Check-Cap (NASDAQ:CHEK) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Check-Cap (NASDAQ:CHEK) in a research note issued to investors on Wednesday morning. The brokerage issued a sell rating on the medical research company’s stock.

Check-Cap Price Performance

Shares of NASDAQ CHEK opened at $0.62 on Wednesday. The stock has a market capitalization of $3.64 million, a PE ratio of -0.21 and a beta of 0.25. Check-Cap has a one year low of $0.61 and a one year high of $3.45. The business’s fifty day moving average price is $1.04 and its 200-day moving average price is $1.62.

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.